Current treatments in Parkinson's including the proposal of an innovative dopamine microimplant

Velázquez-Paniagua, Mireya; Vázquez-Alvarez, A. M.; Valverde-Aguilar, Guadalupe; Vergara-Aragón, P.

doi:10.1016/j.hgmx.2015.10.006

Cited by 4 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, TiO 2 -DA complexes synthesized by the sol-gel method were implanted on the caudate nucleus of unilaterally lesioned rats, significantly recovering motor crossing and rearing behaviours. Subsequent studies identified that the oxidation process of DA was delayed for up to 30 days [ 158 , 159 , 160 ]; similarly, DA release from the device in vivo was corroborated up to 360 days post-implantation [ 161 ]. Other DA stabilization approaches on TiO 2 have opted for the design of nanohybrid organic-inorganic composites, in which CS-DA composites were coated with titania [ 162 ].…”

Section: Controlled Drug Delivery On Parkinson’s Diseasementioning

confidence: 99%

Nanomedicine in the Face of Parkinson’s Disease: From Drug Delivery Systems to Nanozymes

Padilla-Godínez

Ruiz-Ortega

Guerra-Crespo

2022

Cells

View full text Add to dashboard Cite

The complexity and overall burden of Parkinson’s disease (PD) require new pharmacological approaches to counteract the symptomatology while reducing the progressive neurodegeneration of affected dopaminergic neurons. Since the pathophysiological signature of PD is characterized by the loss of physiological levels of dopamine (DA) and the misfolding and aggregation of the alpha-synuclein (α-syn) protein, new proposals seek to restore the lost DA and inhibit the progressive damage derived from pathological α-syn and its impact in terms of oxidative stress. In this line, nanomedicine (the medical application of nanotechnology) has achieved significant advances in the development of nanocarriers capable of transporting and delivering basal state DA in a controlled manner in the tissues of interest, as well as highly selective catalytic nanostructures with enzyme-like properties for the elimination of reactive oxygen species (responsible for oxidative stress) and the proteolysis of misfolded proteins. Although some of these proposals remain in their early stages, the deepening of our knowledge concerning the pathological processes of PD and the advances in nanomedicine could endow for the development of potential treatments for this still incurable condition. Therefore, in this paper, we offer: (i) a brief summary of the most recent findings concerning the physiology of motor regulation and (ii) the molecular neuropathological processes associated with PD, together with (iii) a recapitulation of the current progress in controlled DA release by nanocarriers and (iv) the design of nanozymes, catalytic nanostructures with oxidoreductase-, chaperon, and protease-like properties. Finally, we conclude by describing the prospects and knowledge gaps to overcome and consider as research into nanotherapies for PD continues, especially when clinical translations take place.

show abstract